General Information of Drug (ID: DMVXGU0)

Drug Name
RG7596 Drug Info
Indication
Disease Entry ICD 11 Status REF
Haematological malignancy 2B33.Y Phase 2 [1]
Cross-matching ID
TTD Drug ID
DMVXGU0

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Polatuzumab vedotin DMF6Y0L Diffuse large B-cell lymphoma 2A81 Approved [3]
DCDS-4501A DMQRCX5 Diffuse large B-cell lymphoma 2A81 Phase 2 [4]
Polivy DMFCIKN Mantle cell lymphoma 2A85.5 Phase 2 [5]
MGD010 DMA368V Autoimmune disease 4A40-4A45 Phase 1 [6]
CD79-targeted immunotoxins DMWP63C Non-hodgkin lymphoma 2B33.5 Investigative [2]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
B-cell-specific glycoprotein B29 (CD79B) TTBN5I7 CD79B_HUMAN Modulator [2]

References

1 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800034127)
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2852).
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
4 Marine-Sourced Anti-Cancer and Cancer Pain Control Agents in Clinical and Late Preclinical Development. Mar Drugs. 2014 January; 12(1): 255-278.
5 Polatuzumab Vedotin: First Global Approval. Drugs. 2019 Sep;79(13):1467-1475.
6 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)